Literature DB >> 15378729

Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.

Subhash C Sinha1, Lian-Sheng Li, Shin-Ichi Watanabe, Eiton Kaltgrad, Fujie Tanaka, Christoph Rader, Richard A Lerner, Carlos F Barbas.   

Abstract

Prodrugs of potent aldehyde analogues of the anticancer drug doxorubicin (Dox) were synthesized. These prodrugs were efficiently activated by antibody 93F3 and no drug formation was observed in the absence of 93F3 in either phosphate buffered saline or cell culture media. In the presence of antibody 93F3, these prodrugs were activated and decreased the proliferation of human cancer cells in in vitro proliferation assays.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378729     DOI: 10.1002/chem.200400419

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  4 in total

1.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

2.  Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Authors:  Ulrich Wuellner; Julia I Gavrilyuk; Carlos F Barbas
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

3.  Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.

Authors:  Sunny Abraham; Fang Guo; Lian-Sheng Li; Christoph Rader; Cheng Liu; Carlos F Barbas; Richard A Lerner; Subhash C Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

4.  The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.

Authors:  Krishna Mohan Bajjuri; Yuan Liu; Cheng Liu; Subhash C Sinha
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.